MCID: CNJ013
MIFTS: 64

Conjunctivitis malady

Categories: Eye diseases, Infectious diseases, Cardiovascular diseases, Respiratory diseases, Gastrointestinal diseases, Nephrological diseases

Aliases & Classifications for Conjunctivitis

Aliases & Descriptions for Conjunctivitis:

Name: Conjunctivitis 12 29 52 3 42 14 69
Madras Eye 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6195
ICD10 33 H10 H10.9
ICD9CM 35 372.30
MeSH 42 D003231
NCIt 47 C34504
UMLS 69 C0009763

Summaries for Conjunctivitis

CDC : 3 Conjunctivitis is often called "pink eye" because it can cause the white of the eye to take on a pink or red color. Symptoms of pink eye can vary but typically include redness or swelling of the white of the eye.

MalaCards based summary : Conjunctivitis, also known as madras eye, is related to neonatal stroke and goodpasture syndrome, and has symptoms including bloodshot eye, conjunctival congestion and redness of eye. An important gene associated with Conjunctivitis is PLG (Plasminogen), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Oralair and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and t cells, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A conjunctival disease characterized by an inflammation of the conjunctiva, the outermost layer of the eye and the inner surface of the eyelids.

Wikipedia : 71 Conjunctivitis, also known as pink eye, is inflammation of the outermost layer of the white part of the... more...

Related Diseases for Conjunctivitis

Diseases in the Conjunctivitis family:

Acute Conjunctivitis Chronic Conjunctivitis
Bacterial Conjunctivitis

Diseases related to Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 582)
id Related Disease Score Top Affiliating Genes
1 neonatal stroke 31.0 IFNG IL2 IL4
2 goodpasture syndrome 30.9 CXCL8 IFNG IL2 IL6
3 thelaziasis 30.9 CCL11 IL13 IL2 IL4 IL5
4 hepatitis 29.6 IFNG IL2 IL6
5 tuberculosis 29.6 IL2 IL4 IL6
6 sarcoma 29.4 IL2 IL4
7 stomatitis 29.3 CXCL8 IL2 IL6
8 burns 29.3 CXCL8 IFNG IL6
9 pyoderma gangrenosum 29.3 CXCL8 IFNG IL6
10 actinic keratosis 29.1 IL13 IL2 IL4 IL5 RNASE3
11 periarthritis 29.0 IFNG IL2 IL4
12 epidermolysis bullosa 29.0 CCL11 IFNG IL13 IL4 IL5 RNASE3
13 congestive heart failure 28.9 FOXP3 IFNG IL2 IL4 IL6
14 rheumatoid arthritis 28.9 CXCL8 FOXP3 ICAM1 IFNG IL2 IL4
15 exophthalmos 28.7 CXCL8 IFNG IL2 IL4 IL6 TLR3
16 tracheitis 28.6 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
17 acute hemorrhagic conjunctivitis 12.3
18 allergic conjunctivitis 12.2
19 ligneous conjunctivitis 12.2
20 inclusion conjunctivitis 12.2
21 chronic conjunctivitis 12.1
22 acute contagious conjunctivitis 12.1
23 bacterial conjunctivitis 12.1
24 pseudomembranous conjunctivitis 12.1
25 giant papillary conjunctivitis 12.0
26 vernal conjunctivitis 11.9
27 papillary conjunctivitis 11.9
28 acute conjunctivitis 11.9
29 chronic follicular conjunctivitis 11.9
30 plasminogen deficiency, type i 11.8
31 conjunctivitis with pseudomembrane 11.8
32 ophthalmia neonatorum 11.8
33 serous conjunctivitis except viral 11.7
34 parasitic conjunctivitis 11.7
35 simple chronic conjunctivitis 11.7
36 rosacea conjunctivitis 11.7
37 blepharoconjunctivitis 11.3
38 angelucci's syndrome 11.2
39 measles 11.0
40 allergic rhinitis 10.9
41 reactive arthritis 10.9
42 ocular cicatricial pemphigoid 10.9
43 avian influenza 10.9
44 coccidioidomycosis 10.9
45 conjunctival folliculosis 10.8
46 lacrimal duct defect 10.7
47 hypogonadotropic hypogonadism 13 with or without anosmia 10.7
48 hypogonadotropic hypogonadism 15 with or without anosmia 10.7
49 hypogonadotropic hypogonadism 4 with or without anosmia 10.7
50 hypogonadotropic hypogonadism 18 with or without anosmia 10.7

Comorbidity relations with Conjunctivitis via Phenotypic Disease Network (PDN): (show all 21)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Blepharitis
Bronchitis Chronic Myocardial Ischemia
Decubitus Ulcer Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Hypothyroidism
Iron Deficiency Anemia Ischemic Heart Disease
Osteoporosis Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Swallowing Disorders
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Conjunctivitis:



Diseases related to Conjunctivitis

Symptoms & Phenotypes for Conjunctivitis

UMLS symptoms related to Conjunctivitis:


bloodshot eye, conjunctival congestion, redness of eye, discharge from eye

MGI Mouse Phenotypes related to Conjunctivitis:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 IL4 IL5 IL6 NLRP3 PLG PTGDR2
2 immune system MP:0005387 10.24 CCL11 EPX FOXP3 ICAM1 IFNG IL13
3 digestive/alimentary MP:0005381 10.22 FOXP3 ICAM1 IFNG IL13 IL2 IL33
4 homeostasis/metabolism MP:0005376 10.22 PLG PTGDR2 TLR3 FOXP3 ICAM1 IFNG
5 cellular MP:0005384 10.19 ICAM1 FOXP3 IFNG IL13 IL2 IL33
6 endocrine/exocrine gland MP:0005379 10.16 FOXP3 ICAM1 IFNG IL13 IL2 IL33
7 integument MP:0010771 9.97 FOXP3 ICAM1 IFNG IL13 IL33 IL4
8 liver/biliary system MP:0005370 9.86 FOXP3 IFNG IL2 IL4 IL5 IL6
9 neoplasm MP:0002006 9.7 ICAM1 IFNG IL2 IL5 IL6 PLG
10 reproductive system MP:0005389 9.7 IL33 IL4 IL5 IL6 NLRP3 PLG
11 respiratory system MP:0005388 9.36 IL5 IL6 PLG TLR3 CCL11 FOXP3

Drugs & Therapeutics for Conjunctivitis

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Oralair 17 Greer Labs Approved April 2014

Drugs for Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 328)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
2
Zinc Approved Phase 4,Phase 3,Phase 2 7440-66-6 32051 23994
3
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
4
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
5
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2 82410-32-0 3454
6
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 9004-61-9 53477741 24759
7
Glycerol Approved, Experimental Phase 4,Phase 3,Phase 2 56-81-5 753
8
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75614-87-8, 51-45-6 774
9
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 299-42-3 9294
10
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
11
Tobramycin Approved, Investigational Phase 4,Phase 3 32986-56-4 5496 36294
12
Acitretin Approved Phase 4 55079-83-9 6437841 5284513
13
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 90-82-4 7028
14
Loteprednol Approved Phase 4,Phase 3,Phase 2 82034-46-6, 129260-79-3 444025 9865442
15
Alcaftadine Approved Phase 4,Phase 3 147084-10-4 19371515
16
Naphazoline Approved Phase 4,Phase 3 835-31-4 4436
17
Pheniramine Approved Phase 4 86-21-5 4761
18
Dipivefrin Approved Phase 4,Phase 3,Phase 2 52365-63-6 3105
19
Ethanol Approved Phase 4,Phase 2 64-17-5 702
20
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757 53477783
21
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
22
Montelukast Approved Phase 4 158966-92-8 5281040
23
Ivermectin Approved, Vet_approved Phase 4 70288-86-7 6474909 46936176
24
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
25
Ketotifen Approved Phase 4,Phase 3,Phase 2,Phase 1 34580-14-8, 34580-13-7 3827
26
Azithromycin Approved Phase 4,Phase 3,Phase 2 83905-01-5 55185 53477736 447043
27
Norgestimate Approved Phase 4,Phase 3,Phase 2 35189-28-7 6540478
28
Ketorolac Approved Phase 4,Phase 2,Phase 3 74103-06-3, 66635-83-4 3826
29
Tranilast Approved, Investigational Phase 4 53902-12-8 93543
30
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
31
Ofloxacin Approved Phase 4,Phase 2,Phase 3 82419-36-1 4583
32
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
33
Permethrin Approved, Investigational Phase 4 52645-53-1 40326
34
Desloratadine Approved, Investigational Phase 4,Phase 3 100643-71-8 124087
35
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 354812-41-2, 151096-09-2 152946
36
Trimethoprim Approved, Vet_approved Phase 4,Phase 3 738-70-5 5578
37
Epinastine Approved, Investigational Phase 4,Phase 3 80012-43-7 3241
38
Menthol Approved Phase 4 2216-51-5 16666
39
Albendazole Approved, Vet_approved Phase 4 54965-21-8 2082
40
Gatifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 112811-59-3 5379
41
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
42
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2 57-63-6 5991
43
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 6447131 17753757
44
Levofloxacin Approved, Investigational Phase 4,Phase 2,Phase 3 100986-85-4 149096
45
Povidone-iodine Approved Phase 4,Phase 3 25655-41-8
46
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
47
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
48
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 2,Phase 3 67-97-0 6221 10883523 5280795
49
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
50
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538

Interventional clinical trials:

(show top 50) (show all 775)
id Name Status NCT ID Phase
1 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4
2 A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis Unknown status NCT01533480 Phase 4
3 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4
4 The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Unknown status NCT01346371 Phase 4
5 Efficacy and Safety of LAIS® Mites Sublingual Tablets Unknown status NCT02277483 Phase 4
6 Ocular Allergy Treatment Practical Impact Trial Unknown status NCT01808768 Phase 4
7 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4
8 Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo Unknown status NCT01246921 Phase 4
9 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
10 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4
11 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4
12 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4
13 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4
14 A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome Unknown status NCT00344721 Phase 4
15 A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis Completed NCT00655109 Phase 4
16 Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis Completed NCT01119287 Phase 4
17 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4
18 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Completed NCT01697969 Phase 4
19 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4
20 Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4
21 Moxifloxacin vs. Polytrim for Conjunctivitis Completed NCT00581542 Phase 4
22 A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4
23 Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan Completed NCT02251613 Phase 4
24 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4
25 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4
26 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4
27 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4
28 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4
29 Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4
30 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4
31 Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis Completed NCT00534794 Phase 4
32 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4
33 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4
34 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4
35 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge Model Completed NCT00689078 Phase 4
36 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4
37 Assessment of Alcon's Ocular Image Quantification System Completed NCT01282138 Phase 4
38 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4
39 A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209) Completed NCT00311844 Phase 4
40 Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms Completed NCT00891436 Phase 4
41 Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis Completed NCT00705159 Phase 4
42 Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006) Completed NCT02256553 Phase 4
43 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4
44 Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model Completed NCT01730872 Phase 4
45 Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed NCT01179412 Phase 4
46 An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo Completed NCT01439815 Phase 4
47 Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda Completed NCT01211327 Phase 4
48 The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing Completed NCT01128556 Phase 4
49 Montelukast as a Controller of Atopic Syndrome Completed NCT00559546 Phase 4
50 Tolerability of Grazax in Patients With Hayfever in Real Life Settings Completed NCT01433510 Phase 4

Search NIH Clinical Center for Conjunctivitis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: conjunctivitis

Genetic Tests for Conjunctivitis

Genetic tests related to Conjunctivitis:

id Genetic test Affiliating Genes
1 Conjunctivitis 29

Anatomical Context for Conjunctivitis

MalaCards organs/tissues related to Conjunctivitis:

39
Eye, Testes, T Cells, Bone, Lung, Prostate, Breast

Publications for Conjunctivitis

Articles related to Conjunctivitis:

(show top 50) (show all 1849)
id Title Authors Year
1
Dynamic modelling of strategies for the control of acute haemorrhagic conjunctivitis outbreaks in schools in Changsha, China (2004-2015). ( 27758731 )
2017
2
Diagnosis and management of allergic conjunctivitis in pediatric patients. ( 28052798 )
2017
3
Vernal-like conjunctivitis in a western lowland gorilla (Gorilla gorilla gorilla). ( 28058762 )
2017
4
Effects of Exposure to Ozone on the Ocular Surface in an Experimental Model of Allergic Conjunctivitis. ( 28046113 )
2017
5
High Sporozoite Antibody Titers in Conjunction with Microscopically Detectable Blood Infection Display Signatures of Protection from Clinical Malaria. ( 28533773 )
2017
6
Role of CCL7 in Type I Hypersensitivity Reactions in Murine Experimental Allergic Conjunctivitis. ( 27956527 )
2017
7
Self-Reported Allergic Rhinitis and/or Allergic Conjunctivitis Associate with IL13 rs20541 Polymorphism in Finnish Adult Asthma Patients. ( 28273659 )
2017
8
Redness response phenotypes of allergic conjunctivitis in an allergen challenge chamber. ( 28007090 )
2017
9
Angiolymphoid Hyperplasia with Eosinophilia Accompanying Vernal Conjunctivitis. ( 27993267 )
2017
10
Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates. ( 28078599 )
2017
11
Superoxide dismutase 3 attenuates experimental Th2-driven allergic conjunctivitis. ( 28063939 )
2017
12
Prevalence of feline herpesvirus-1, feline calicivirus, Chlamydophila felis and Mycoplasma felis DNA and associated risk factors in cats in Spain with upper respiratory tract disease, conjunctivitis and/or gingivostomatitis. ( 26919892 )
2016
13
Cicatrizing Conjunctivitis in a Patient Diagnosed With Drug Reaction With Eosinophilia and Systemic Symptoms/Drug-Induced Hypersensitivity Syndrome but With Features of Stevens-Johnson Syndrome. ( 27078005 )
2016
14
Topical Plasminogen as Adjunctive Treatment in Recurrent Ligneous Conjunctivitis. ( 27065432 )
2016
15
Allergic contact conjunctivitis and cross-reaction between phenylephrine and epinephrine due to phenylephrine eye drops. ( 27788888 )
2016
16
Efficacy and safety of an eye wash solution in allergic conjunctivitis after conjunctival allergen challenge. ( 27788889 )
2016
17
Clinical and histopathological aspects in two cases of ligneous conjunctivitis. ( 27516042 )
2016
18
Expression of TSLP and Downstream Molecules IL-4, IL-5, and IL-13 on the Eye Surface of Patients with Various Types of Allergic Conjunctivitis. ( 27504196 )
2016
19
Frequency of reactive arthritis, uveitis, and conjunctivitis in Japanese patients with bladder cancer following intravesical BCG therapy: A 20-year, two-centre retrospective study. ( 27825571 )
2016
20
Allergic rhino-conjunctivitis continued to increase in Swedish children up to 2007, but asthma and eczema levelled off from 1991. ( 27102081 )
2016
21
Beware traumatic conjunctivitis: airbags can cause severe alkali eye injuries. ( 27083383 )
2016
22
High incidence of dry eye in young children with allergic conjunctivitis in Southwest China. ( 27226346 )
2016
23
Effects of carvedilol reduce conjunctivitis through changes in inflammation, NGF and VEGF levels in a rat model. ( 27168839 )
2016
24
Ocular Pharmacology of Tear Film, Dry Eye, and Allergic Conjunctivitis. ( 27913889 )
2016
25
Case report: Providencia stuartii conjunctivitis. ( 27528052 )
2016
26
Development of Allergic Conjunctivitis Induced by House Dust Mite Extract From Dermatophagoides pteronyssinus. ( 27074380 )
2016
27
Component-resolved diagnostics in vernal conjunctivitis. ( 27454864 )
2016
28
TRPV1 Antagonist Suppresses Allergic Conjunctivitis in a Murine Model. ( 27726468 )
2016
29
The effects of povidone iodine (pH 4.2) on patients with adenoviral conjunctivitis. ( 27524529 )
2016
30
Study of the prevalence and association of ocular chlamydial conjunctivitis in women with genital infection by Chlamydia trachomatis, Mycoplasma genitalium and Candida albicans attending outpatient clinic. ( 27588273 )
2016
31
Ocular Onset of Paraneoplastic Pemphigus Presenting as Hyperemic Conjunctivitis and Massive Bilateral Eyelid Ulceration: A Case Report and Literature Review. ( 27537424 )
2016
32
Neonatal Orbital Abscess Secondary to Pseudomonas Aeruginosa Conjunctivitis. ( 27464455 )
2016
33
Whole Body Magnetic Resonance Imaging Features in Diffuse Idiopathic Skeletal Hyperostosis in Conjunction with Clinical Variables to Whole Body MRI and Clinical Variables in Ankylosing Spondylitis. ( 26669910 )
2016
34
Antibiotic eye drops for conjunctivitis in infants at nursery. ( 27789492 )
2016
35
Treating allergic conjunctivitis: A once-daily medication that provides 24-hour symptom relief. ( 27466061 )
2016
36
Histopathological clues in the diagnosis of fungal infection by Scedosporium in a case of endophthalmitis starting as conjunctivitis. ( 26968327 )
2016
37
Topical Application of Interleukin-28A Attenuates Allergic Conjunctivitis in an Ovalbumin-Induced Mouse Model. ( 26886894 )
2016
38
Fatty acid microemulsion for the treatment of neonatal conjunctivitis: quantification, characterisation and evaluation of antimicrobial activity. ( 27766599 )
2016
39
A major outbreak of conjunctivitis caused by coxsackievirus A24, RAcunion, January to April 2015. ( 27387200 )
2016
40
Successful Treatment with Chronic Conjunctivitis: Removal of Tarsoconjunctival Crypt. ( 27478360 )
2016
41
Allergic Conjunctivitis and the Associated Risk of Migraine Among Children: A Nationwide Population-based Cohort Study. ( 27382919 )
2016
42
Correlation between acute conjunctivitis and Asian dust on ocular surfaces. ( 27142484 )
2016
43
Bronchoalveolar lavage cellular analyses in conjunction with high-resolution computed tomography imaging as a diagnostic intervention for patients with suspected interstitial lung disease. ( 27185993 )
2016
44
Sequelae from Epidemic Viral Conjunctivitis Can Be Associated with Inflammatory Trachoma in Schoolchildren? ( 27628039 )
2016
45
The effect of footwear adapted with a multi-curved rocker sole in conjunction with knee-ankle-foot orthoses on walking in poliomyelitis subjects: a pilot study. ( 27982715 )
2016
46
Combined Use of Rituximab and Intravenous Immunoglobulin for Severe Autoimmune Cicatricial Conjunctivitis-An Interventional Case Series. ( 27661067 )
2016
47
Comment on: Systemic approach to managing vernal conjunctivitis in clinical practice and severity grading system and treatment algorithm. ( 27609172 )
2016
48
Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis. ( 27192186 )
2016
49
Gonococcal Conjunctivitis Despite Successful Treatment of Male Urethritis Syndrome. ( 26760182 )
2016
50
Co-existing ligneous conjunctivitis and IgG4-related disease. ( 27609168 )
2016

Variations for Conjunctivitis

Expression for Conjunctivitis

Search GEO for disease gene expression data for Conjunctivitis.

Pathways for Conjunctivitis

Pathways related to Conjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 CCL11 CXCL8 EPX ICAM1 IFNG IL13
2
Show member pathways
13.65 CCL11 CXCL8 IFNG IL13 IL2 IL4
3
Show member pathways
13.56 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
4
Show member pathways
13.43 CCL11 CXCL8 IL13 IL2 IL4 IL5
5
Show member pathways
13.42 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
6
Show member pathways
13.31 CCL11 CXCL8 IL13 IL2 IL4 IL5
7
Show member pathways
12.9 CXCL8 IFNG IL2 IL6 TLR3
8
Show member pathways
12.69 FOXP3 IFNG IL13 IL2 IL4 IL5
9
Show member pathways
12.69 CXCL8 ICAM1 IFNG IL13 IL2 IL33
10 12.57 FOXP3 IFNG IL2 IL4 TLR3
11
Show member pathways
12.5 ICAM1 IFNG IL2 IL4
12
Show member pathways
12.47 IFNG IL2 IL4 IL5 IL6
13
Show member pathways
12.47 CCL11 CXCL8 EPX FOXP3 ICAM1 IFNG
14
Show member pathways
12.43 ICAM1 IFNG IL2 IL4 IL6 PLG
15
Show member pathways
12.4 CCL11 CXCL8 IFNG IL13 IL4 IL5
16
Show member pathways
12.31 IFNG IL13 IL2 IL4 IL5 IL6
17
Show member pathways
12.29 CXCL8 IFNG IL6 TLR3
18
Show member pathways
12.25 CCL11 CXCL8 IFNG IL4 IL6
19
Show member pathways
12.19 CXCL8 IFNG IL13 IL2 IL4 IL5
20 12.11 CXCL8 ICAM1 IFNG IL2 IL4 IL6
21 12.09 IFNG IL2 IL4 IL5 IL6 PTGDR2
22
Show member pathways
12.07 IL13 IL2 IL5 TLR3
23 12.07 CCL11 CXCL8 ICAM1 IL13 IL4 IL6
24
Show member pathways
11.99 IFNG IL2 IL6 TLR3
25
Show member pathways
11.96 IFNG IL4 IL6 TLR3
26 11.93 CXCL8 IFNG IL6
27
Show member pathways
11.92 CXCL8 FOXP3 ICAM1 IL6
28 11.9 CXCL8 ICAM1 IFNG IL6
29 11.89 CXCL8 ICAM1 IL6
30 11.88 IL4 IL5 IL6
31 11.88 CXCL8 IFNG IL6
32
Show member pathways
11.85 CXCL8 FOXP3 IFNG IL2 IL4 IL5
33 11.85 IFNG IL13 IL2 IL33 IL4 IL5
34 11.83 FOXP3 ICAM1 IL4 IL5 IL6
35 11.82 CXCL8 IFNG IL6
36
Show member pathways
11.78 CXCL8 ICAM1 IFNG IL2 IL6
37 11.77 IFNG IL2 IL6
38 11.77 CXCL8 IL6 NLRP3
39 11.73 CCL11 CXCL8 IL13 IL4 IL5 IL6
40
Show member pathways
11.71 FOXP3 IL2 IL4
41 11.71 IFNG IL2 IL6
42 11.68 CCL11 IL4 IL5
43 11.67 CXCL8 ICAM1 IFNG IL13 IL2 IL4
44 11.66 CXCL8 ICAM1 IL13 IL4 IL6
45 11.62 CXCL8 ICAM1 IFNG IL6
46 11.61 CXCL8 IFNG IL6
47 11.58 IFNG IL2 IL6
48 11.55 ICAM1 IL6 PLG
49 11.51 CXCL8 ICAM1 IFNG
50
Show member pathways
11.46 FOXP3 IFNG IL2

GO Terms for Conjunctivitis

Cellular components related to Conjunctivitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 CCL11 CXCL8 EPX IFNG IL13 IL2
2 external side of plasma membrane GO:0009897 9.55 ICAM1 IFNG IL13 IL4 IL6
3 extracellular space GO:0005615 9.44 CCL11 CXCL8 EPX ICAM1 IFNG IL13

Biological processes related to Conjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
id Name GO ID Score Top Affiliating Genes
1 chemotaxis GO:0006935 9.97 CCL11 CXCL8 IL4 PTGDR2
2 positive regulation of protein phosphorylation GO:0001934 9.96 IFNG IL2 IL4 TLR3
3 defense response GO:0006952 9.93 CXCL8 EPX NLRP3 TLR3
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.93 ICAM1 IL6 NLRP3 TLR3
5 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.91 IL4 IL5 IL6
6 response to ethanol GO:0045471 9.91 ICAM1 IL13 IL2 IL4
7 defense response to virus GO:0051607 9.91 IFNG IL33 IL6 NLRP3 TLR3
8 cellular response to tumor necrosis factor GO:0071356 9.9 CCL11 CXCL8 ICAM1 IL6
9 movement of cell or subcellular component GO:0006928 9.89 CXCL8 IFNG IL13
10 negative regulation of inflammatory response GO:0050728 9.89 FOXP3 IL2 NLRP3
11 response to virus GO:0009615 9.89 CCL11 FOXP3 IFNG TLR3
12 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.88 ICAM1 IL4 IL5 IL6
13 neutrophil chemotaxis GO:0030593 9.87 CCL11 CXCL8 IFNG
14 cellular response to interferon-gamma GO:0071346